Get the Stockscreener App
1.21
6.14%
0.07
After Hours:
1.20
-0.01
-0.83%
Inflarx N V stock is traded at $1.21, with a volume of 1.20M.
It is up +6.14% in the last 24 hours and up +27.91% over the past month.
InflaRx NV is a biopharmaceutical company applying proprietary technologies to discover, develop and commercialize potent and specific inhibitors of the complement activation factor known as C5a and its receptor C5aR. With its therapeutic product candidates, vilobelimab and izicopan, the company targets C5a and its receptor C5aR to selectively inhibit the powerful inflammatory response observed in a wide variety of autoimmune and other inflammatory diseases elicited through C5a/C5aR activation. Its product candidate, GOHIBIC (vilobelimab), is a novel intravenously delivered anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
See More
Previous Close:
$1.14
Open:
$1.17
24h Volume:
1.20M
Relative Volume:
2.66
Market Cap:
$87.47M
Revenue:
$208.60K
Net Income/Loss:
$-58.59M
P/E Ratio:
-1.3204
EPS:
-0.9164
Net Cash Flow:
$-47.11M
1W Performance:
+27.37%
1M Performance:
+27.91%
6M Performance:
-3.20%
1Y Performance:
+10.00%
1-Day Range:
$1.14
$1.25
1-Week Range:
$0.9545
$1.25
52-Week Range:
$0.7113
$1.94
Inflarx N V Stock (IFRX) Company Profile
Compare IFRX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IFRX
Inflarx N V
|
1.21 | 82.41M | 208.60K | -58.59M | -47.11M | -0.9164 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Inflarx N V Stock (IFRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-03-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Sep-02-25 | Resumed | H.C. Wainwright | Buy |
| May-29-25 | Downgrade | Raymond James | Strong Buy → Outperform |
| Apr-29-25 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-05-23 | Upgrade | Guggenheim | Neutral → Buy |
| Feb-28-22 | Downgrade | Guggenheim | Buy → Neutral |
| Oct-28-21 | Upgrade | Raymond James | Outperform → Strong Buy |
| Mar-11-21 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-06-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Oct-08-20 | Initiated | H.C. Wainwright | Buy |
| Jun-17-20 | Initiated | BTIG Research | Buy |
| Apr-30-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jun-05-19 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jun-05-19 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-05-19 | Downgrade | JP Morgan | Overweight → Underweight |
| Jun-05-19 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jun-05-19 | Downgrade | SunTrust | Buy → Hold |
| Jan-29-19 | Initiated | Robert W. Baird | Outperform |
| Dec-10-18 | Initiated | Credit Suisse | Outperform |
| Jul-13-18 | Initiated | BMO Capital Markets | Outperform |
| Jun-28-18 | Initiated | Raymond James | Outperform |
| Jun-28-18 | Initiated | SunTrust | Buy |
| Feb-08-18 | Initiated | B. Riley FBR, Inc. | Buy |
View All
Inflarx N V Stock (IFRX) Latest News
InflaRx NV stock (NL0012661870): Why does its anti-inflammatory pipeline matter more now for biotech - AD HOC NEWS
InflaRx Highlights New Izicopan Data Showing No CYP3A4 Time-Dependent Inhibition - TipRanks
InflaRx (Nasdaq: IFRX) reports izicopan data showing no CYP3A4 time‑dependent inhibition - Stock Titan
New lab data point to lower liver toxicity risk for InflaRx pill - Stock Titan
InflaRx NV stock: Why this biotech innovator merits your watchlist now - AD HOC NEWS
InflaRx receives Nasdaq notification - MSN
Investment Review: Is InflaRx NV a top pick in the sector2026 Highlights & AI Forecasted Stock Moves - baoquankhu1.vn
IFRX Technical Analysis & Stock Price Forecast - Intellectia AI
InflaRx NV stock: Biotech innovator or high-risk bet? - AD HOC NEWS
InflaRx Sets April 23, 2026 AGM to Approve 2025 Accounts, Board Mandates and New LTIP - TipRanks
InflaRx (NASDAQ: IFRX) 2026 AGM to expand share pool, renew buyback - Stock Titan
InflaRx N : Dutch Board Report including KPMG Auditor Report 2025 (InflaRx N.V. Dutch Board Report + Auditor Report 2025) - marketscreener.com
InflaRx N : Long-term Incentive Plan “LTIP 2026” (LTIP 2026 FINAL) - marketscreener.com
InflaRx Announces Participation in the Raymond James 2026 Biotech Innovation Symposium - bitget.com
IFRX Stock News Today | Earnings, Events & Price Alerts - intellectia.ai
InflaRx presents phase 3 vilobelimab data at dermatology meeting By Investing.com - Investing.com South Africa
InflaRx Highlights Clinical Activity of Vilobelimab in Pyoderma Gangrenosum in Late-Breaker Oral Presentation at 2026 American Academy of Dermatology Annual Meeting - Bitget
InflaRx presents phase 3 vilobelimab data at dermatology meeting - Investing.com
InflaRx Highlights Clinical Activity of Vilobelimab in - GlobeNewswire
InflaRx NV (IFRX) price target decreased by 17.33% to 9.03 - MSN
Sell Signal: Can InflaRx NV deliver consistent dividends2026 Summary & High Accuracy Investment Entry Signals - baoquankhu1.vn
InflaRx N.V. (NASDAQ:IFRX) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Treasury Yields: Can InflaRx NV sustain earnings growth2026 Earnings Surprises & Daily Stock Momentum Reports - baoquankhu1.vn
Can InflaRx's Vilobelimab Stage A Revival In Pyoderma Gangrenosum? - RTTNews
HC Wainwright Forecasts InflaRx's Q3 Earnings (NASDAQ:IFRX) - MarketBeat
Analyst Upgrade: Is InflaRx NV a top pick in the sector2026 Action & Low Volatility Stock Recommendations - baoquankhu1.vn
If You Invested $1,000 in Inflarx (IFRX) - Stock Titan
Aug Shorts: Can InflaRx NV sustain earnings growthMarket Movement Recap & Community Trade Idea Sharing - baoquankhu1.vn
Bear Alert: Is InflaRx NV a top pick in the sector2026 Gainers & Daily Momentum Trading Reports - baoquankhu1.vn
InflaRx NV (IFRX) reports Q4 loss, lags revenue estimates - MSN
Raymond James raises Inflarx stock price target on drug trial data - Investing.com India
Raymond James raises Inflarx stock price target on drug trial data By Investing.com - Investing.com South Africa
InflaRx Survival Hopes Rest On Izicopan - Citeline News & Insights
InflaRx (NASDAQ:IFRX) Given New $14.00 Price Target at Guggenheim - MarketBeat
Guggenheim cuts Inflarx stock price target on model update to $14 By Investing.com - Investing.com South Africa
Guggenheim cuts Inflarx stock price target on model update to $14 - Investing.com Canada
Q1 Earnings Forecast for InflaRx Issued By HC Wainwright - MarketBeat
InflaRx (IFRX) posts 2025 loss, relies on cash runway and grants - Stock Titan
InflaRx N.V. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
InflaRx NV reports results for the quarter ended December 31Earnings Summary - TradingView
IFRX: Izicopan's promising Phase 2a data drives strategic focus and extends cash runway to mid-2027 - TradingView
InflaRx (NASDAQ:IFRX) Issues Earnings Results, Meets Expectations - MarketBeat
InflaRx N.V. (IFRX) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance
InflaRx Shifts Strategy to Izicopan as 2025 Results Extend Cash Runway to 2027 - TipRanks
Inflarx reports full year 2025 results and highlights key achievements and expected milestones - marketscreener.com
InflaRx Reports Full Year 2025 Results and Highlights Key Achievements and Expected Milestones - The Manila Times
InflaRx (IFRX) narrows 2025 loss, shifts focus to izicopan growth - Stock Titan
IFRX: Izicopan advances as the lead asset with strong Phase 2a data, cost cuts, and extended cash runway - TradingView
After focusing on izicopan, InflaRx says cash lasts until mid-2027 - Stock Titan
InflaRx to present Phase 3 pyoderma gangrenosum data at AAD By Investing.com - Investing.com South Africa
Inflarx N V Stock (IFRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):